MF
LAB icon

Manchester Financial’s Standard BioTools LAB Stock Holding History

Manchester Financial’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-500
Closed -$2K – 375
2021
Q1 		$2K Sell
500
-150
-23% -$824 ﹤0.01% 632
2020
Q4 		$4K Sell
650
-625
-49% -$4.11K ﹤0.01% 480
2020
Q3 		$9K Buy
+1,275
New +$8.8K 0.01% 327

Other funds holding LAB

ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Manchester Financial's LAB Position: Q2 2021 in Review

Manchester Financial sold out of Standard BioTools (LAB) in Q2 2021, closing a stake of 500 shares — an estimated $2K sold.

Manchester Financial first reported a position in LAB in Q3 2020 and held it in 3 quarters. The position peaked at $9K in Q3 2020. 113 funds tracked by Wall St. Rank hold LAB as of Q2 2021.

  • Manchester Financial reported no remaining Standard BioTools position as of Q2 2021 after selling out during the quarter.
  • Manchester Financial sold 500 Standard BioTools shares in Q2 2021, an estimated $2K.
  • Manchester Financial first reported a position in Standard BioTools in Q3 2020 and held it in 3 quarters.
  • Manchester Financial's Standard BioTools position peaked at $9K in Q3 2020.
  • 113 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2021.

Based on Manchester Financial's 13F filing for Q2 2021, filed 21 Jul 2021.